| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Investigations |
Department of Obstetrics and Gynecology [N. H., R. E. K., M. K., M. S.] and Department of Experimental Oncology [A. K.], Technical University, D-81675 Munich, Germany; Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital Rotterdam, 3075 Rotterdam, The Netherlands [M. P. L., M. E. M-v. G., J. G. M. K., J. A. F.]; and Department of Obstetrics and Gynecology, University of Hamburg, D-20246 Hamburg, Germany [F. J.]
Risk assessment and prediction of response to treatment are prerequisites for individualized adjuvant therapy decisions in breast cancer. The strong prognostic impact of the two invasion factors urokinase-type plasminogen activator (uPA) and its inhibitor, plasminogen activator inhibitor type 1 (PAI-1), in breast cancer has recently been validated at level-I evidence. This article considers the predictive impact of uPA/PAI-1 on response to adjuvant chemo- and endocrine therapy in 3424 primary breast cancer patients from two different data sets. uPA and PAI-1 antigen levels were measured by ELISA in primary tumor tissue extracts. After a median follow-up of 83 months, uPA/PAI-1 has a significant impact on disease-free survival in Cox multivariate analysis (P < 0.001; hazard ratio, 2.0; 95% confidence interval, 1.8–2.3). Patients with high uPA/PAI-1 levels benefit more strongly from adjuvant chemotherapy than those with low levels. This effect is seen as a significant interaction between chemotherapy and uPA/PAI-1 for the entire collective (P < 0.003; hazard ratio, 0.68; 95% confidence interval, 0.53–0.88) and separately within nodal subgroups. This enhanced benefit in the high uPA/PAI-1 patients occurs over and above the significant impact of both therapies in all patients. We find no corresponding significant interaction between endocrine therapy and uPA/PAI-1; i.e., no significant difference in benefit between patients with high and low uPA/PAI-1. In conclusion, uPA and PAI-1 levels in primary tumor tissue provide clinically relevant information on relapse risk and treatment response that will help to tailor adjuvant therapy concepts in breast cancer, accounting for individual biological tumor characteristics.
This article has been cited by other articles:
|
|
 |
|
  O. Hartmann, F. Spyratos, N. Harbeck, D. Dietrich, A. Fassbender, M. Schmitt, S. Eppenberger-Castori, V. Vuaroqueaux, F. Lerebours, K. Welzel, et al. DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy Clin. Cancer Res., January 1, 2009; 15(1): 315 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem., December 1, 2008; 54(12): e11 - e79. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5287 - 5312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dorn, M. Schmitt, R. Kates, B. Schmalfeldt, M. Kiechle, A. Scorilas, E. P. Diamandis, and N. Harbeck Primary Tumor Levels of Human Tissue Kallikreins Affect Surgical Success and Survival in Ovarian Cancer Patients Clin. Cancer Res., March 15, 2007; 13(6): 1742 - 1748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-S. Schrohl, M. E. Meijer-van Gelder, M. N. Holten-Andersen, I. J. Christensen, M. P. Look, H. T. Mouridsen, N. Brunner, and J. A. Foekens Primary Tumor Levels of Tissue Inhibitor of Metalloproteinases-1 Are Predictive of Resistance to Chemotherapy in Patients with Metastatic Breast Cancer Clin. Cancer Res., December 1, 2006; 12(23): 7054 - 7058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Sternlicht, A. M. Dunning, D. H. Moore, P. D.P. Pharoah, D. G. Ginzinger, K. Chin, J. W. Gray, F. M. Waldman, B. A.J. Ponder, and Z. Werb Prognostic Value of PAI1 in Invasive Breast Cancer: Evidence That Tumor-Specific Factors Are More Important Than Genetic Variation in Regulating PAI1 Expression. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2107 - 2114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhang, X.-O. Shu, Q. Cai, Z. Ruan, Y.-T. Gao, and W. Zheng Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival. Clin. Cancer Res., October 15, 2006; 12(20): 6037 - 6042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Urban, V. Vuaroqueaux, M. Labuhn, M. Delorenzi, P. Wirapati, E. Wight, H.-J. Senn, C. Benz, U. Eppenberger, and S. Eppenberger-Castori Increased Expression of Urokinase-Type Plasminogen Activator mRNA Determines Adverse Prognosis in ErbB2-Positive Primary Breast Cancer J. Clin. Oncol., September 10, 2006; 24(26): 4245 - 4253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Alfano, I. Iaccarino, and M. P. Stoppelli Urokinase Signaling through Its Receptor Protects against Anoikis by Increasing BCL-xL Expression Levels J. Biol. Chem., June 30, 2006; 281(26): 17758 - 17767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Dua, C. M. Isacke, and G. P.H. Gui The Intraductal Approach to Breast Cancer Biomarker Discovery J. Clin. Oncol., March 1, 2006; 24(7): 1209 - 1216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Duffy Predictive Markers in Breast and Other Cancers: A Review Clin. Chem., March 1, 2005; 51(3): 494 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. M.-v. Gelder, M. P. Look, H. A. Peters, M. Schmitt, N. Brunner, N. Harbeck, J. G. M. Klijn, and J. A. Foekens Urokinase-Type Plasminogen Activator System in Breast Cancer: Association with Tamoxifen Therapy in Recurrent Disease Cancer Res., July 1, 2004; 64(13): 4563 - 4568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Span, E. Waanders, P. Manders, J. J.T.M. Heuvel, J. A. Foekens, M. A. Watson, L. V.A.M. Beex, and F. C.G.J. Sweep Mammaglobin Is Associated With Low-Grade, Steroid Receptor-Positive Breast Tumors From Postmenopausal Patients, and Has Independent Prognostic Value for Relapse-Free Survival Time J. Clin. Oncol., February 15, 2004; 22(4): 691 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Manders, V. C. G. Tjan-Heijnen, P. N. Span, N. Grebenchtchikov, J. A. Foekens, L. V. A. M. Beex, and C. G. J. Sweep Predictive Impact of Urokinase-Type Plasminogen Activator: Plasminogen Activator Inhibitor Type-1 Complex on the Efficacy of Adjuvant Systemic Therapy in Primary Breast Cancer Cancer Res., January 15, 2004; 64(2): 659 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Manders, F. C. G. J. Sweep, V. C. G. Tjan-Heijnen, A. Geurts-Moespot, D. T. H. van Tienoven, J. A. Foekens, P. N. Span, J. Bussink, and L. V. A. M. Beex Vascular Endothelial Growth Factor Independently Predicts the Efficacy of Postoperative Radiotherapy in Node-Negative Breast Cancer Patients Clin. Cancer Res., December 15, 2003; 9(17): 6363 - 6370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Qin, W. Zhu, C. Wagner-Mann, and E. R. Sauter Nipple Aspirate Fluid Expression of Urokinase-Type Plasminogen Activator, Plasminogen Activator Inhibitor-1, and Urokinase-Type Plasminogen Activator Receptor Predicts Breast Cancer Diagnosis and Advanced Disease Ann. Surg. Oncol., October 1, 2003; 10(8): 948 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Matrisian, G. W. Sledge Jr., and S. Mohla Extracellular Proteolysis and Cancer: Meeting Summary and Future Directions Cancer Res., October 1, 2003; 63(19): 6105 - 6109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Goldhirsch, W. C. Wood, R. D. Gelber, A. S. Coates, B. Thurlimann, and H.-J. Senn Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer J. Clin. Oncol., September 1, 2003; 21(17): 3357 - 3365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-S. Schrohl, M. Holten-Andersen, F. Sweep, M. Schmitt, N. Harbeck, J. Foekens, and N. Brunner Tumor Markers: From Laboratory To Clinical Utility Mol. Cell. Proteomics, June 1, 2003; 2(6): 378 - 387. [Full Text] [PDF]
|
|
|
|
|
|
I. Zemzoum, R. E. Kates, J. S. Ross, P. Dettmar, M. Dutta, C. Henrichs, S. Yurdseven, H. Hofler, M. Kiechle, M. Schmitt, et al. Invasion Factors uPA/PAI-1 and HER2 Status Provide Independent and Complementary Information on Patient Outcome in Node-Negative Breast Cancer J. Clin. Oncol., March 15, 2003; 21(6): 1022 - 1028. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
